Navigation Links
Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
Date:2/28/2013

r which proceeds are to be used for general corporate and working capital purposes including the funding of clinical trials
  • Initiated the TAKSTA Phase 2 clinical trial in patients with prosthetic joint infections (PJIs)
  • Initiated the oral solithromycin Phase 3 clinical trial in patients with community-acquired bacterial pneumonia
  • Clinical program updateThe company is primarily focused on the development of its two lead clinical-stage antibiotic candidates, the fluoroketolide, solithromycin, in clinical development for CABP and uncomplicated gonococcal infections and TAKSTA, the oral antibiotic being developed for prosthetic joint infections.  The company expects the following events to occur during 2013:

    Solithromycin

  • 1H13: End of Phase 2 meeting with the FDA
  • 2H13: Initiation of the IV-to-oral Phase 3 clinical trial in CABP, subject to available resources
  • TAKSTA

  • 4Q13: Top-line results of the Phase 2 trial in PJI patients
  • Financial GuidanceCempra expects its research and development expense to increase due to the initiation of the solithromycin Phase 3 and the TAKSTA Phase 2 clinical trials during the fourth quarter of 2012.  The company's cash and equivalents are expected to be sufficient to fund current operations into 2015.  This projection does not include initiation of the planned IV-to-oral solithromycin Phase 3 trial.

    Conference Call and WebcastThe conference call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers. Please specify to the operator that you would like to join the "Cempra, Inc., Full year 2012 Financial Results Call, conference ID#: 12497222." The conference call will be webcast live under the investor relations section of Cempra's website at www.cempra.com, and will be archived there for 30 days following the call. Please visit Cempra's website several
    '/>"/>

    SOURCE Cempra, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. United States Patent and Trademark Office to Require Signed NDA Affects Many Reports Wysebridge
    2. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
    3. Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
    4. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
    5. Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
    6. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
    7. Neuland Labs Reports Third Quarter Fiscal Year 2013 Financial Results
    8. Intraocular Lens (IOL) Market Worth $3.8 Billion By 2018 Say New Research Report at ReportsnReports.com
    9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
    10. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
    11. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/1/2015)... May 1, 2015 Investor-Edge ... Technologies Ltd (NASDAQ: GENE ), Agilent Technologies ... Inc. (NYSE: TMO ), Sequenom Inc. (NASDAQ: ... PKI ). Free research report on Genetic Technologies ... Thursday, April 30, 2015, the NASDAQ Composite ended ...
    (Date:5/1/2015)... , May 1, 2015 ... Production Market by Product (Equipment, Consumables), by Type (Monoclonal, ... Diagnostic Labs, Research Institutes) - Analysis & Global ... studies the global Antibody Production Market for the ... is expected to reach $2.572 Billion by 2019 ...
    (Date:4/30/2015)... Blythewood, South Carolina (PRWEB) May 01, 2015 ... steam system services, is extremely proud to announce that ... have been named as a winner of a Queen’s ... business success for the design and manufacture of a ... is the revolutionary alternative to traditional steam flow ...
    (Date:4/30/2015)... , April 30, 2015   Tamir Biotechnology , ... an update on its Ebola antiviral therapy program. ... candidates, TMR004, is currently being evaluated and considered by ... battle against Ebola. During the first quarter of 2015, ... Meeting To Accelerate The Evaluation of Potential Treatments and ...
    Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4
    ... In LESS Instrumentation Is Selected for Industry Leader LESS ... Jan. 29 Cambridge Endo, a pioneer in the ... Surgery or SPA) market, is pleased to announce that ... industry leaders selected to be on a LESS panel ...
    ... of first-in-class multivalent therapies for cancerREDWOOD SHORES, Calif., Jan. ... it has entered into a $24 million private placement ... this financing, investments will be made in three tranches: ... December 31, 2009 and $8 million before December 31, ...
    ... evolves content and advertising offerings to life science community , ... ... to its online community for life science careers and industry resources. ... a partnership with the Journal of Visualized Experiments (JoVE)., , , ...
    Cached Biology Technology:Cleveland Clinic Selects Laparoendoscopic Single-Site Surgery (LESS) as One of the Top Ten Innovations of 2009 2Omnitura Therapeutics Announces Private Placement Financing 2BioSpace Partners with Journal of Visualized Experiments (JoVE) to Offer Peer-Reviewed Scientific Video Content on BioSpace.com 2BioSpace Partners with Journal of Visualized Experiments (JoVE) to Offer Peer-Reviewed Scientific Video Content on BioSpace.com 3
    (Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
    (Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
    (Date:4/2/2015)... , April 2, 2015 At its ... Salt Lake City , the American College of ... five new directors to its Board.  Members of the ... ACMG and for forming and advancing its policies and ... genetics profession. "It,s an eventful time in ...
    Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
    ... According to the World Bank, China has one of ... only to the United States in emissions of carbon dioxide, ... home to 20 of the worlds 30 most air-polluted cities. ... acid rain and water pollution, scientists at UC Riverside and ...
    ... the structure of human bones is vastly different than ... how some debilitating bone disorders are treated. Researchers ... in Newmarket, and the BAM Federal Institute of Materials ... toughness and stiffness of bone is predominantly due to ...
    ... Ninety-seven years after an American was hanged in London in ... British history, forensic science at Michigan State University is producing ... Crippen was hanged for murdering and dismembering his showgirl wife, ... the police in hot pursuit. Loaded with enough sordid details ...
    Cached Biology News:UC-Riverside partners with Chinese university to address China's environmental problems 2UC-Riverside partners with Chinese university to address China's environmental problems 3New research on structure of bones raises questions for treatment of osteoporosis 2Science casts doubt on famous British murder case 2Science casts doubt on famous British murder case 3
    Porcine IFN-gamma ELISpot Development Module...
    RECOMBINANT EQUINE TNF ALPHA Product Type: Recombinant Protein...
    TEMPLIPHI HT SEQ AMPL KIT, 1 EA. Category: Sequencing Template Amplification....
    ... Kit #4 detects apoptosis on the ... permeability of cell membranes. This kit contains ... iodide nucleic acid stains. YO-PRO-1 stain selectively ... cells and labels them with moderate green ...
    Biology Products: